6F6S
CRYSTAL STRUCTURE OF EBOLAVIRUS GLYCOPROTEIN IN COMPLEX WITH benztropine
Summary for 6F6S
| Entry DOI | 10.2210/pdb6f6s/pdb |
| Related | 6F5U 6F6I 6F6N |
| Descriptor | Envelope glycoprotein,Envelope glycoprotein,GP1, Envelope glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total) |
| Functional Keywords | ebola virus, filoviridae, envelope glycoprotein, protein inhibitor complex, ibuprofen, benztropine, bepridil, paroxetine, sertraline, toremifene, viral protein |
| Biological source | Zaire ebolavirus (strain Mayinga-76) (ZEBOV) More |
| Total number of polymer chains | 2 |
| Total formula weight | 58337.03 |
| Authors | Ren, J.,Zhao, Y.,Fry, E.E.,Stuart, D.I. (deposition date: 2017-12-06, release date: 2018-01-03, Last modification date: 2024-01-17) |
| Primary citation | Ren, J.,Zhao, Y.,Fry, E.E.,Stuart, D.I. Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection. J. Med. Chem., 61:724-733, 2018 Cited by PubMed Abstract: Here, we show that four chemically divergent approved drugs reported to inhibit Ebolavirus infection, benztropine, bepridil, paroxetine and sertraline, directly interact with the Ebolavirus glycoprotein. Binding of these drugs destabilizes the protein, suggesting that this may be the mechanism of inhibition, as reported for the anticancer drug toremifene and the painkiller ibuprofen, which bind in the same large cavity on the glycoprotein. Crystal structures show that the position of binding and the mode of interaction within the pocket vary significantly between these compounds. The binding constants (K) determined by thermal shift assay correlate with the protein-inhibitor interactions as well as with the antiviral activities determined by virus cell entry assays, supporting the hypothesis that these drugs inhibit viral entry by binding the glycoprotein and destabilizing the prefusion conformation. Details of the protein-inhibitor interactions of these complexes and their relation with binding affinity may facilitate the design of more potent inhibitors. PubMed: 29272110DOI: 10.1021/acs.jmedchem.7b01249 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.29 Å) |
Structure validation
Download full validation report
